Janney Montgomery Scott LLC Buys 101,733 Shares of Kenvue Inc. $KVUE

Posted by Francis Steltz on Jul 2nd, 2026

Janney Montgomery Scott LLC raised its stake in Kenvue Inc. (NYSE:KVUE – Free Report) by 14.5% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 805,630 shares of the company’s stock after acquiring an additional 101,733 shares during the period. Janney Montgomery Scott LLC’s holdings in Kenvue were worth $13,889,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of the stock. Arrowstreet Capital Limited Partnership acquired a new position in Kenvue in the second quarter valued at about $6,528,000. Jump Financial LLC grew its stake in Kenvue by 210.6% during the second quarter. Jump Financial LLC now owns 54,823 shares of the company’s stock worth $1,147,000 after buying an additional 37,170 shares in the last quarter. AXA S.A. grew its stake in Kenvue by 21.1% during the second quarter. AXA S.A. now owns 48,892 shares of the company’s stock worth $1,023,000 after buying an additional 8,524 shares in the last quarter. NewEdge Advisors LLC increased its holdings in Kenvue by 219.1% in the 2nd quarter. NewEdge Advisors LLC now owns 97,481 shares of the company’s stock valued at $2,040,000 after buying an additional 66,930 shares during the period. Finally, The Manufacturers Life Insurance Company increased its holdings in Kenvue by 0.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 1,873,705 shares of the company’s stock valued at $39,217,000 after buying an additional 10,885 shares during the period. 97.64% of the stock is currently owned by institutional investors.

Kenvue Price Performance

Shares of NYSE:KVUE opened at $19.33 on Thursday. Kenvue Inc. has a one year low of $14.02 and a one year high of $22.87. The company has a debt-to-equity ratio of 0.67, a current ratio of 0.98 and a quick ratio of 0.70. The company has a market cap of $37.11 billion, a price-to-earnings ratio of 22.74, a PEG ratio of 1.45 and a beta of 0.54. The firm has a 50 day simple moving average of $17.76 and a 200 day simple moving average of $17.68.

Kenvue (NYSE:KVUE – Get Free Report) last posted its earnings results on Thursday, May 7th. The company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. The firm had revenue of $3.91 billion for the quarter, compared to analysts’ expectations of $3.84 billion. Kenvue had a net margin of 10.61% and a return on equity of 20.81%. The company’s revenue was up 4.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.24 earnings per share. Research analysts predict that Kenvue Inc. will post 1.16 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, May 27th. Investors of record on Wednesday, May 13th were issued a dividend of $0.2075 per share. The ex-dividend date of this dividend was Wednesday, May 13th. This represents a $0.83 annualized dividend and a dividend yield of 4.3%. Kenvue’s dividend payout ratio (DPR) is 97.65%.

Analysts Set New Price Targets

Several equities analysts have recently commented on KVUE shares. Citigroup dropped their target price on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a research report on Wednesday, April 15th. Weiss Ratings raised shares of Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, June 15th. Argus upgraded shares of Kenvue to a “hold” rating in a research report on Friday, March 6th. UBS Group cut their target price on Kenvue from $19.00 to $18.00 and set a “neutral” rating for the company in a research note on Tuesday, April 7th. Finally, Zacks Research raised Kenvue from a “hold” rating to a “strong-buy” rating in a report on Friday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and twelve have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $19.33.

Check Out Our Latest Report on Kenvue

Insiders Place Their Bets

In related news, General Counsel Matthew Orlando sold 38,491 shares of the business’s stock in a transaction on Friday, May 8th. The stock was sold at an average price of $17.66, for a total transaction of $679,751.06. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 1.59% of the stock is owned by corporate insiders.

About Kenvue

(Free Report)

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.